• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Feldman Roman

    4/15/25 7:01:32 PM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology
    Get the next $GXAI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Feldman Roman

    (Last) (First) (Middle)
    C/O GAXOS.AI INC.
    101 EISENHOWER PARKWAY SUITE 300

    (Street)
    ROSELAND NJ 07068

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    GAXOS.AI INC. [ GXAI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/14/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (right to buy) $1.11 04/14/2025 A(1) 25,000 04/15/2026 04/14/2030 Common Stock 25,000 $0 25,000 D
    Explanation of Responses:
    1. The options were issued pursuant to the Issuer's 2022 Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant.
    /s/ Roman Feldman 04/15/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GXAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GXAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GXAI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Gaxos.ai Inc.

      10-Q - GAXOS.AI INC. (0001895618) (Filer)

      5/15/25 4:30:53 PM ET
      $GXAI
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 10-K filed by Gaxos.ai Inc.

      10-K - GAXOS.AI INC. (0001895618) (Filer)

      3/28/25 5:27:35 PM ET
      $GXAI
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 8-K12B filed by Gaxos.ai Inc.

      8-K12B - GAXOS.AI INC. (0001895618) (Filer)

      3/4/25 4:15:18 PM ET
      $GXAI
      Computer Software: Prepackaged Software
      Technology

    $GXAI
    Leadership Updates

    Live Leadership Updates

    See more
    • Gaxos Health Expands Medical Advisory Board

      Roseland, NJ, April 25, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that Gaxos Health has expanded its Medical Advisory Board with the appointment of Dr. Eric Margolis and Dr. Jeff Pavell. "The addition of top medical talent to our Medical Advisory Board reflects our continued commitment to pursuing a best-in-class solution for Gaxos Health," said Vadim Mats, CEO of Gaxos.AI. "An advisory board of experts in their respective fields will allow to create a better product and advancing our mission of creating value for shareholders." Dr. Eric Margolis, M.D.  is a Board-Ce

      4/25/24 8:45:00 AM ET
      $GXAI
      Computer Software: Prepackaged Software
      Technology

    $GXAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $GXAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gaxos Labs Launches UnGPT.ai Setting a New Standard in Humanized AI

      Roseland, NJ, May 21, 2025 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced the official launch of UnPGT.ai, a tool that makes text created by generative artificial intelligence sound natural and human. UnGPT introduces a real-time rewriting engine designed to convert machine-generated text into authentic, human-quality content without compromising meaning or context. UnGPT uses a proprietary multi-pass transformation model that outperforms leading AI detection tools and addresses one of the industry's fastest growing concerns: the need for undetectable, high-quality output in se

      5/21/25 8:00:00 AM ET
      $GXAI
      Computer Software: Prepackaged Software
      Technology
    • Gaxos Labs Approved for Listing on Amazon Web Services (AWS) Marketplace

      Roseland, NJ , May 07, 2025 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that its product, Gaxos Labs for Game Developers and Publishers, has been officially approved for listing on Amazon Web Services (AWS) Marketplace, one of the cloud industry's largest software distribution platforms.  The approval marks a significant milestone in the Company's go-to-market strategy, enabling seamless deployment of Gaxos Labs by millions of AWS customers across 245 countries and territories. AWS Marketplace listing streamlines procurement for enterprise clients, simplifies software billi

      5/7/25 8:00:00 AM ET
      $GXAI
      Computer Software: Prepackaged Software
      Technology
    • Gaxos Health Announces Launch of AI-Powered App

      Roseland, NJ, April 08, 2025 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced the official launch of the AI-enabled Gaxos Health mobile application for iOS and Android for its customers.  The new AI-driven app is designed to personalize and optimize individual health outcomes through smart technology and science-backed routines. The Gaxos Health app leverages proprietary algorithms to deliver goal-based wellness protocols including nutrition, fitness, supplementation, and behavioral coaching. "We are thrilled to announce the launch of the Gaxos Health app," said Vadim Mats, CEO

      4/8/25 7:30:00 AM ET
      $GXAI
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Director Holzer Adam

      4 - GAXOS.AI INC. (0001895618) (Issuer)

      4/15/25 7:03:36 PM ET
      $GXAI
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Director Grayson Scott

      4 - GAXOS.AI INC. (0001895618) (Issuer)

      4/15/25 7:02:46 PM ET
      $GXAI
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by Director Feldman Roman

      4 - GAXOS.AI INC. (0001895618) (Issuer)

      4/15/25 7:01:32 PM ET
      $GXAI
      Computer Software: Prepackaged Software
      Technology

    $GXAI
    Financials

    Live finance-specific insights

    See more
    • Gaxos Acquires Rights to AI-enabled Technology from Top Biohacking App

      Roseland, NJ, March 13, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that it had acquired the rights to use certain AI-enabled technology from a top biohacking app, "Ultiself," in order to facilitate the development of its tech for Gaxos Health. The integration of Ultiself's proprietary technology into Gaxos Health's proposed product offering will enable enhanced customization and user experience aligning with modern-day consumer's demands for custom and efficient solutions. This move is expected to accelerate Gaxos Health's development and help solidify its positio

      3/13/24 8:30:00 AM ET
      $GXAI
      Computer Software: Prepackaged Software
      Technology

    $GXAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Gaxos.ai Inc.

      SC 13G - GAXOS.AI INC. (0001895618) (Subject)

      11/14/24 3:30:50 PM ET
      $GXAI
      Computer Software: Prepackaged Software
      Technology